Carroll Amy R, Coleman Robert L, Sood Anil K
Department of Gynecologic Oncology, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Front Biosci (Schol Ed). 2011 Jan 1;3(1):82-97. doi: 10.2741/s134.
Cytotoxic therapy and surgery have improved outcomes for patients with gynecologic malignancies over the last twenty years, but women's cancers still account for over ten percent of cancer related deaths annually. Insights into the pathogenesis of cancer have led to the development of drugs that target molecular pathways essential to tumor survival including angiogenesis, DNA repair, and apoptosis. This review outlines several of the promising new biologically targeted drugs currently being tested to treat gynecologic malignancies.
在过去二十年中，细胞毒性疗法和手术改善了妇科恶性肿瘤患者的治疗效果，但女性癌症仍占每年癌症相关死亡人数的10%以上。对癌症发病机制的深入了解促使了针对肿瘤生存所必需的分子途径（包括血管生成、DNA修复和细胞凋亡）的药物的开发。本综述概述了目前正在测试用于治疗妇科恶性肿瘤的几种有前景的新型生物靶向药物。
